Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Marso, S.; H. Daniels, Gilbert; Brown-Frandsen, K.; Kristensen, P.; Mann, J.; A. Nauck, Michael; E. Nissen, Steven; Pocock, S.; Poulter, N.; Ravn, L.; M. Steinberg, W.; Stockner, Mette; Zinman, B.; Bergenstal, R.; B. Buse, J.

doi:10.1056/NEJMoa1603827

Public

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Shared by NobleBlocks on Jun 13, 2016 • 12:00 AM UTC

Authors:

S. Marso

Gilbert H. Daniels

K. Brown-Frandsen

Abstract

BACKGROUND The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive lirag...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!